Selecta Biosciences (SELB) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SELB shares.
View SELB analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12-month price targets for Selecta Biosciences' stock. Their SELB share price forecasts range from $4.00 to $9.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 368.8% from the stock's current price.
View analysts price targets for SELB or view top-rated stocks among Wall Street analysts.

Selecta Biosciences' stock was trading at $1.13 on January 1st, 2023. Since then, SELB shares have increased by 13.3% and is now trading at $1.28.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SELB earnings forecast.

Selecta Biosciences, Inc. (NASDAQ:SELB) posted its earnings results on Thursday, May, 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.03. The firm had revenue of $5.94 million for the quarter, compared to analyst estimates of $14.60 million. Selecta Biosciences had a negative net margin of 18.21% and a negative trailing twelve-month return on equity of 17.67%.

ETFs with the largest weight of Selecta Biosciences (NASDAQ:SELB) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and First Trust Dow Jones Select Microcap Index Fund (FDM) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Selecta Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.57%), Sphera Funds Management LTD. (1.52%), JPMorgan Chase & Co. (1.30%), Acadian Asset Management LLC (0.98%), Geode Capital Management LLC (0.79%) and Renaissance Technologies LLC (0.70%). Insiders that own company stock include Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe.
View institutional ownership trends.

Shares of SELB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SELB stock can currently be purchased for approximately $1.28.

Selecta Biosciences (NASDAQ:SELB) has a market capitalization of $196.39 million and generates $110.78 million in revenue each year. The company earns $35.38 million in net income (profit) each year or ($0.09) on an earnings per share basis.

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The official website for the company is selectabio.com. The company can be reached via phone at (617) 923-1400, via email at lstern@soleburytrout.com, or via fax at 617-924-3454.